Blueprint Medicines Corporation(BPMC)_个股概要_股票价格_最新资讯_行情走势_历史数据

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BPMC Blueprint Medicines Corporation

交易中 11-19 13:19:58 EST

92.40

+2.22

+2.46%

最高92.66	最低88.97	成交量20.80万
今开89.55	昨收90.18	日振幅4.09%
总市值58.70亿	流通市值58.05亿	总股本6,353万
成交额1,895万	换手率0.33%	流通股本6,283万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"BPMC","market":"US","secType":"STK","nameCN":"Blueprint Medicines Corporation","latestPrice":92.4,"timestamp":1732040386157,"preClose":90.18,"halted":0,"volume":207971,"delay":0,"floatShares":62829423,"shares":63525838,"eps":-2.059319,"marketStatus":"交易中","marketStatusCode":2,"change":2.22,"latestTime":"11-19 13:19:58 EST","open":89.55,"high":92.66,"low":88.97,"amount":18949212.154135,"amplitude":0.040918,"askPrice":92.47,"askSize":8,"bidPrice":92.28,"bidSize":50,"shortable":3,"etf":0,"ttmEps":-2.059319,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1732050000000},"adr":0,"listingDate":1430366400000,"adjPreClose":90.18,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":89.69,"preClose":90.18,"latestTime":"09:29 EST","volume":517,"amount":46408.62391,"timestamp":1732026599999},"postHourTrading":{"tag":"盘后","latestPrice":90.18,"preClose":90.18,"latestTime":"19:28 EST","volume":13280,"amount":1197655.06,"timestamp":1731976118241},"volumeRatio":0.603795,"impliedVol":0.4625,"impliedVolPercentile":0.1548},"requestUrl":"/m/hq/s/BPMC/wiki","defaultTab":"wiki","newsList":[{"id":"2483306119","title":"Blueprint Medicines Corporation盘中异动 大幅下跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483306119","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483306119?lang=zh_cn&edition=full","pubTime":"2024-11-16 00:00","pubTimestamp":1731686427,"startTime":"0","endTime":"0","summary":"北京时间2024年11月16日00时00分，Blueprint Medicines Corporation股票出现异动，股价快速下挫5.04%。Blueprint Medicines Corporation股票所在的生物技术行业中，整体跌幅为3.43%。其相关个股中，Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Celularity Inc C/Wts 16/07/2026 、Cero Therapeutics Holdings, Inc.涨幅较大，Tc Biopharm  Plc、Cero Therapeutics Holdings, Inc.、Elevai Labs, Inc.较为活跃，换手率分别为4225.61%、557.57%、352.43%，振幅较大的相关个股有Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Celularity Inc C/Wts 16/07/2026 ，振幅分别为134.58%、129.73%、110.59%。Blueprint Medicines Corporation公司简介：蓝图医药公司是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111600002798e42fef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111600002798e42fef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0053671581.USD","BPMC","BK4139","BK4505"],"gpt_icon":0},{"id":"2483050876","title":"美国研究综述-思科、Freshpet、Nvidia","url":"https://stock-news.laohu8.com/highlight/detail?id=2483050876","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483050876?lang=zh_cn&edition=full","pubTime":"2024-11-14 20:06","pubTimestamp":1731585982,"startTime":"0","endTime":"0","summary":"美国研究综述-思科、Freshpet、Nvidia路透11月14日 - 华尔街证券分析师周四调整了对思科、Freshpet 和 Nvidia 等几家美国上市公司的评级和目标价。要闻 * 思科CSCO.O：杰富瑞将目标价从53美元上调至66美元 * Freshpet Inc FRPT.O：奥本海默将目标价从155美元上调至180美元  * ICU Medical Inc ICUI.O：Raymond James将目标价从190美元上调至205美元  * Kronos Bio Inc KRON.O：TD Cowen将目标价从买入下调至持有 * Nvidia Corp NVDA.O：奥本海默将目标价从 150 美元上调至 175 美元 以下是路透周四报导的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nL4T3ML18A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AIT","CBSH","BTMD","IE00BZ1G4Q59.USD","ALLO","BIIB","CAKE","CSCO","LU0868494708.USD","ALSN","APD","EE","CPT","CRVS","LU1894683348.USD","AVB","BK4209","LU0234572021.USD","SG9999002232.USD","LU2106854487.HKD","LU1244550577.SGD","ALMS","AXTA","AZTA","AROC","CNNE","AMGN","APEI","IE00BFXG1179.USD","LU0300736492.USD","SPRY","COGT","BK4550","BRBR","BPMC","ACRV","CPAY","CPB","CTRA","AESI","CHGG","BKR","LU1244550494.USD","CHX","CAVA","ADAP","FDMT","DOX","SLRN","BWXT"],"gpt_icon":0},{"id":"2482089175","title":"Blueprint Medicines Corporation涨0.31% 股价突破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2482089175","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482089175?lang=zh_cn&edition=full","pubTime":"2024-11-12 22:53","pubTimestamp":1731423229,"startTime":"0","endTime":"0","summary":"北京时间2024年11月12日22时53分，Blueprint Medicines Corporation股票出现波动，股价大幅上涨0.31%。截至发稿，该股报100.18美元/股，成交量1.3045万股，换手率0.02%，振幅1.65%。Blueprint Medicines Corporation股票所在的生物技术行业中，整体跌幅为0.17%。Blueprint Medicines Corporation公司简介：蓝图医药公司是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111222535098e42188&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111222535098e42188&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BPMC","LU0053671581.USD","BK4139"],"gpt_icon":0},{"id":"2481100893","title":"Blueprint Medicines Corporation跌1.61% 股价跌破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2481100893","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481100893?lang=zh_cn&edition=full","pubTime":"2024-11-08 23:05","pubTimestamp":1731078338,"startTime":"0","endTime":"0","summary":"北京时间2024年11月08日23时05分，Blueprint Medicines Corporation股票出现波动，股价大幅下挫1.61%。截至发稿，该股报99.76美元/股，成交量3.3067万股，换手率0.05%，振幅1.57%。Blueprint Medicines Corporation股票所在的生物技术行业中，整体涨幅为0.56%。Blueprint Medicines Corporation公司简介：蓝图医药公司是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108230538abae5093&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108230538abae5093&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BPMC","BK4139","LU0053671581.USD"],"gpt_icon":0},{"id":"1134171571","title":"异动解读 | Blueprint Medicines Corporation股价盘中大涨5.25%,可能与其生物制药业务前景看好有关","url":"https://stock-news.laohu8.com/highlight/detail?id=1134171571","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134171571?lang=zh_cn&edition=full","pubTime":"2024-11-06 02:06","pubTimestamp":1730829991,"startTime":"0","endTime":"0","summary":"2024年11月5日,Blueprint Medicines Corporation股价在盘中出现大涨,最高上涨5.25%,引发市场广泛关注。作为一家专注于治疗罕见疾病的生物制药公司,BPMC正在开发多种潜在药物,如用于系统性肥大细胞增多症的AYVAKIT,治疗肥大细胞相关疾病的BLU-808,以及用于乳腺癌的BLU-956和BLU-222等。分析人士认为,BPMC股价上涨或与投资者对公司药物管线和业务前景的乐观预期有关。机构投资者对BPMC也较为看好,约70%的机构给予买入评级。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | Blueprint Medicines Corporation股价盘中大涨5.25%,可能与其生物制药业务前景看好有关","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BPMC"],"gpt_icon":0},{"id":"2481463696","title":"Blueprint Medicines Corporation盘中异动 大幅上涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481463696","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481463696?lang=zh_cn&edition=full","pubTime":"2024-11-06 01:56","pubTimestamp":1730829400,"startTime":"0","endTime":"0","summary":"北京时间2024年11月06日01时56分，Blueprint Medicines Corporation股票出现异动，股价急速上涨5.01%。Blueprint Medicines Corporation股票所在的生物技术行业中，整体涨幅为1.46%。其相关个股中，Bionomics Ltd Ads Each Rep 180 Ord Shs、Zyversa Therapeutics, Inc.、Psyence Biomedical Ltd.涨幅较大，Zyversa Therapeutics, Inc.、Bionomics Ltd Ads Each Rep 180 Ord Shs、Elevai Labs, Inc.较为活跃，换手率分别为5551.91%、2460.38%、780.13%，振幅较大的相关个股有Bionomics Ltd Ads Each Rep 180 Ord Shs、Zyversa Therapeutics, Inc.、Tc Biopharm  Plc C/Wts 10/02/2028 ，振幅分别为91.40%、56.04%、50.00%。Blueprint Medicines Corporation公司简介：蓝图医药公司是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110601564198e409c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110601564198e409c0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BPMC","LU0053671581.USD","BK4505"],"gpt_icon":0},{"id":"2480619360","title":"Blueprint Medicines Corporation2024财年第三财季实现净利润-56.28百万美元，同比增加58.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2480619360","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480619360?lang=zh_cn&edition=full","pubTime":"2024-11-04 00:00","pubTimestamp":1730649622,"startTime":"0","endTime":"0","summary":"11月4日，Blueprint Medicines Corporation公布财报，公告显示公司2024财年第三财季净利润为-56.28百万美元，同比增加58.00%；其中营业收入为1.28亿美元，同比增加126.27%，每股基本收益为-0.89美元。从资产负债表来看，Blueprint Medicines Corporation总负债8.87亿美元，其中短期债务1.18亿美元，资产负债比为1.36，流动比率为3.32。机构评级：截至2024年11月4日，当前有18家机构对Blueprint Medicines Corporation目标价做出预测，其中目标均价为125.28美元，其中最低目标价为81.00美元，最高目标价为167.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104000027a211d26f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104000027a211d26f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BPMC"],"gpt_icon":0},{"id":"2479942039","title":"美国研究综述-Altair 工程公司、布林克国际公司、梅塔公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2479942039","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479942039?lang=zh_cn&edition=full","pubTime":"2024-10-31 22:41","pubTimestamp":1730385704,"startTime":"0","endTime":"0","summary":"    路透10月31日 - 华尔街证券分析师周四调整了对Altair Engineering、Brinker International和Meta等几家美国上市公司的评级和目标价。要闻 * Altair Engineering Inc   ：尼德姆将其评级从 \"买入 \"下调至 \"持有 * Blackbaud Inc   ：贝雅将其评级从 \"跑赢大盘 \"下调至 \"中性\"。* Brinker International Inc   ：摩根大通将其评级从 \"增持 \"下调至 \"中性\"。* Meta   ：贝尔德将目标价从605美元上调至630美元 以下是路透周四报导的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["META","ATNI","AVT","CDW","ALHC","ATI","ATEC","IE00BMPRXN33.USD","BMRC","AXTA","BG","AX","LU0061474960.USD","BKNG","CAT","CWH","LU2264538146.SGD","ALMS","ADP","AEIS","BL","IE00BMPRXR70.SGD","EAT","ABBV","IE0009354923.USD","TECH","ARCC","AUR","BK4141","ANSS","IE00BFXG0V08.USD","ALRS","AVDL","BIIB","BIO","BRO","IE00BZ199S13.USD","ALTR","BPMC","ARVN","LU1169589451.USD","ALL","BK4140","BLKB","LU1854104046.USD","ALKT","CHRW"],"gpt_icon":1},{"id":"2479390780","title":"Blueprint Medicines Corp 报告截至 9 月 30 日的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2479390780","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479390780?lang=zh_cn&edition=full","pubTime":"2024-10-30 23:17","pubTimestamp":1730301455,"startTime":"0","endTime":"0","summary":"   * Blueprint Medicines Corp   报告，截至9月30日的季度调整后每股亏损89美分，高于去年同期的每股收益2.20美元。* Blueprint Medicines Corp公布的本季度每股收益为亏损89美分。* Blueprint Medicines Corp本季度股价下跌了9.8%，今年迄今为止下跌了9.6%。10月30日 - 预测变化   * 在过去三个月里，分析师的平均盈利预期上升了约 18.7%。华尔街对 Blueprint Medicines Corp 的 12 个月目标价中位数为 128.50  本摘要由 LSEG 10 月 30 日 03:17 p.m. UTC 数据机器生成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Blueprint Medicines Corp 报告截至 9 月 30 日的季度业绩 - 收益摘要","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","BPMC","LU0053671581.USD"],"gpt_icon":0},{"id":"1130332893","title":"异动解读 | 蓝图医药股价大涨13.54% 主因上调重磅药物收入预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1130332893","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130332893?lang=zh_cn&edition=full","pubTime":"2024-10-30 22:30","pubTimestamp":1730298655,"startTime":"0","endTime":"0","summary":"北京时间2024年10月30日,生物制药公司蓝图医药盘中股价大涨13.54%,引发市场广泛关注。分析人士认为,推动BPMC股价大涨的主要原因是该公司上调了其胃肠道癌症药物AYVAKIT在2024财年的净产品收入预期。BPMC目前预计,2024年AYVAKIT的全球净产品收入约为4.75亿至4.8亿美元,较之前的4.35亿至4.5亿美元有所增长。AYVAKIT作为蓝图医药的重磅产品,收入预期的上调无疑令投资者对该公司的长期发展前景更加看好,从而推动股价走高。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BPMC"],"gpt_icon":0},{"id":"2479781309","title":"BUZZ-蓝图药物公司上调 AYVAKIT 财年收入预期后股价上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2479781309","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479781309?lang=zh_cn&edition=full","pubTime":"2024-10-30 22:27","pubTimestamp":1730298427,"startTime":"0","endTime":"0","summary":"    10月30日 - ** Blueprint Medicines   股价上涨7.98%，至90.06美元；开盘价创两个月新高，随后跌幅收窄 ** 该公司提高了其胃肠道癌症药物AYVAKIT在24财年的净产品收入预期** 公司目前预计，2024年AYVAKIT的全球净产品收入约为4.75亿至4.8亿美元，高于之前的4.35亿至4.5亿美元。** BPMC 公布第三季度税前利润为 560.03 亿美元，低于预期的 6100 万美元--LSEG** 该股的平均评级为 \"买入 \"或更高，中位预测价格为 128 美元。** 包括本交易日走势在内，该股今年累计下跌约 3","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","BPMC","BK4139","BK4505"],"gpt_icon":0},{"id":"2479834237","title":"Blueprint Medicines Corporation股价飙升12.67% 市值涨7.54亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479834237","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479834237?lang=zh_cn&edition=full","pubTime":"2024-10-30 21:32","pubTimestamp":1730295166,"startTime":"0","endTime":"0","summary":"北京时间2024年10月30日21时32分，Blueprint Medicines Corporation股票出现波动，股价大幅拉升12.67%。截至发稿，该股报93.97美元/股，成交量17.8673万股，换手率0.28%，振幅3.11%。Blueprint Medicines Corporation股票所在的生物技术行业中，整体跌幅为0.31%。其相关个股中，Tharimmune, Inc.、Ensysce Biosciences, Inc.、Quince Therapeutics, Inc.涨幅较大，Tharimmune, Inc.、Ensysce Biosciences, Inc.、Tc Biopharm  Plc较为活跃，换手率分别为1868.47%、99.77%、17.27%，振幅较大的相关个股有Tharimmune, Inc.、Cormedix Inc.、Ensysce Biosciences, Inc.，振幅分别为38.42%、13.18%、11.49%。Blueprint Medicines Corporation公司简介：蓝图医药公司是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024103021324695bd8e3d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024103021324695bd8e3d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","LU0053671581.USD","BPMC"],"gpt_icon":0},{"id":"2470080128","title":"Blueprint Medicines Corporation盘中异动 大幅上涨5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2470080128","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470080128?lang=zh_cn&edition=full","pubTime":"2024-09-27 22:59","pubTimestamp":1727449155,"startTime":"0","endTime":"0","summary":"北京时间2024年09月27日22时59分，Blueprint Medicines Corporation股票出现波动，股价大幅上涨5.06%。Blueprint Medicines Corporation股票所在的生物技术行业中，整体跌幅为0.51%。其相关个股中，Nls Pharmaceutics Ltd C/Wts 02/02/2026、Onconetix, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Onconetix, Inc.、Seelos Therapeutics, Inc.、Tonix Pharmaceuticals Holding Corp.较为活跃，换手率分别为3807.65%、199.18%、119.57%，振幅较大的相关个股有Pasithea Therapeutics Corp C/Wts 12/08/2026 、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为152.50%、60.69%、51.69%。Blueprint Medicines Corporation公司简介：蓝图医药公司是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409272259159719d262&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409272259159719d262&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0053671581.USD","BK4139","BPMC","BK4505"],"gpt_icon":0},{"id":"2457177394","title":"Blueprint Medicines Corporation盘中异动 股价大跌6.90%","url":"https://stock-news.laohu8.com/highlight/detail?id=2457177394","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457177394?lang=zh_cn&edition=full","pubTime":"2024-08-05 21:31","pubTimestamp":1722864665,"startTime":"0","endTime":"0","summary":"北京时间2024年08月05日21时31分，Blueprint Medicines Corporation股票出现异动，股价快速下跌6.90%。截至发稿，该股报90.05美元/股，成交量1.6144万股，换手率0.03%，振幅0.00%。Blueprint Medicines Corporation股票所在的生物技术行业中，整体跌幅为0.73%。其相关个股中，Zevra Therapeutics, Inc.、Cns Pharmaceuticals, Inc.、Protara Therapeutics, Inc.涨幅较大，Cns Pharmaceuticals, Inc.、Dermata Therapeutics, Inc.、Senti Biosciences, Inc.较为活跃，换手率分别为977.99%、33.00%、13.54%，振幅较大的相关个股有Cue Biopharma, Inc.、Compass Therapeutics, Inc.、Compugen医疗，振幅分别为12.33%、12.19%、10.29%。Blueprint Medicines Corporation公司简介：蓝图医药公司是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240805213105941fe2d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240805213105941fe2d7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LU0053671581.USD","BK4505","BPMC"],"gpt_icon":0},{"id":"2456842912","title":"Blueprint Medicines Corporation跌4.13% 股价跌破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2456842912","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456842912?lang=zh_cn&edition=full","pubTime":"2024-08-02 21:32","pubTimestamp":1722605533,"startTime":"0","endTime":"0","summary":"北京时间2024年08月02日21时32分，Blueprint Medicines Corporation股票出现异动，股价大幅下挫4.13%。截至发稿，该股报96.15美元/股，成交量4.8466万股，换手率0.08%，振幅1.11%。Blueprint Medicines Corporation股票所在的生物技术行业中，整体跌幅为0.66%。其相关个股中，Exicure, Inc.、Os Therapies Incorporated、Moleculin Biotech, Inc.涨幅较大，Exicure, Inc.、Dermata Therapeutics, Inc.、Cns Pharmaceuticals, Inc.较为活跃，换手率分别为268.79%、57.64%、17.90%，振幅较大的相关个股有Exicure, Inc.、Anew Medical Inc C/Wts 21/06/2029 、Coya Therapeutics, Inc.，振幅分别为22.02%、17.87%、14.08%。Blueprint Medicines Corporation公司简介：蓝图医药公司是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024080221321395780c66&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024080221321395780c66&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BPMC","BK4139","LU0053671581.USD","BK4505"],"gpt_icon":0},{"id":"1109081349","title":"异动解读 | Blueprint Medicines公司股价大跌6.23% 财报数据或是主因","url":"https://stock-news.laohu8.com/highlight/detail?id=1109081349","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109081349?lang=zh_cn&edition=full","pubTime":"2024-08-01 22:05","pubTimestamp":1722521151,"startTime":"0","endTime":"0","summary":"Blueprint Medicines公司(BPMC)今日盘中股价大跌6.23%,引发市场广泛关注。分析人士认为,公司最新季度财报数据可能是导致股价大跌的主要原因。\n\n财报显示,BPMC第一季度调整后每股亏损0.80美元,高于分析师平均预期的每股亏损1.29美元。尽管营收同比大增140%至1.3816亿美元,但仍低于华尔街预期的1.0358亿美元。\n\n不过,BPMC股价今年迄今仍上涨17.4%,机构投资者对其长期前景保持乐观。目前19家机构中,有68%给予买入评级,26%给予持有评级。分析师对BPMC未来12个月的目标股价中位数为125美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BPMC"],"gpt_icon":0},{"id":"2456438835","title":"Blueprint Medicines 公司报告截至一月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2456438835","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456438835?lang=zh_cn&edition=full","pubTime":"2024-08-01 21:31","pubTimestamp":1722519112,"startTime":"0","endTime":"0","summary":"   * Blueprint Medicines Corp   报告了截至1月底的季度调整后每股亏损80美分，高于去年同期的每股收益2.19美元。华尔街预期为每股亏损 1.53 美元至 1.07 美元。* Blueprint Medicines Corp公布的本季度每股收益为亏损80美分。* 该公司当季亏损 4999 万美元。* Blueprint Medicines Corp本季度股价上涨了0.5%，今年迄今为止上涨了17.4%。8月1日 - 预测变化   * 在过去三个月中，分析师的平均盈利预期上升了约 6.3%。华尔街对 Blueprint Medicines Corp 的 12 个月目标价中位数为 125.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","BPMC","LU0053671581.USD"],"gpt_icon":0},{"id":"2456480777","title":"Blueprint Medicines Corporation盘中异动 早盘急速跳水5.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2456480777","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456480777?lang=zh_cn&edition=full","pubTime":"2024-08-01 21:30","pubTimestamp":1722519048,"startTime":"0","endTime":"0","summary":"北京时间2024年08月01日21时30分，Blueprint Medicines Corporation股票出现异动，股价急速下跌5.69%。截至发稿，该股报102.14美元/股，成交量10.9727万股，换手率0.18%，振幅0.47%。Blueprint Medicines Corporation股票所在的生物技术行业中，整体涨幅为0.65%。其相关个股中，Immuneering Corporation、Renovaro Inc.、Estrella Immunopharma, Inc.涨幅较大，Immuneering Corporation、Cns Pharmaceuticals, Inc.、Neurosense Therapeutics Ltd.较为活跃，换手率分别为42.73%、36.81%、13.09%，振幅较大的相关个股有Proqr Therapeutics N.V.、Centessa Pharmaceuticals Plc、Neurosense Therapeutics Ltd.，振幅分别为6.22%、4.84%、4.59%。Blueprint Medicines Corporation公司简介：蓝图医药公司是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240801213048aefcb551&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240801213048aefcb551&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LU0053671581.USD","BK4505","BPMC"],"gpt_icon":0},{"id":"2455964056","title":"Blueprint Medicines Corp   预计每股亏损1.29美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2455964056","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455964056?lang=zh_cn&edition=full","pubTime":"2024-07-31 02:57","pubTimestamp":1722365838,"startTime":"0","endTime":"0","summary":"   * Blueprint Medicines Corp    将于8月1日公布截至2024年6月30日的财报，预计季度收入将有所增长。* 根据LSEG的数据，17位分析师的平均预期显示，这家总部位于马萨诸塞州剑桥市的公司预计将实现79.9%的营收增长，从去年同期的5757万美元增至1.03575亿美元。* LSEG 的分析师平均预计 Blueprint Medicines Corp 每股亏损 1.29 美元。* 华尔街对 Blueprint Medicines Corp 的 12 个月目标价中位数为 125.00 美元，高于上一交易日的收盘价 110.34 美元。7月30日 - 以前季度业绩。除非另有说明，所有数字均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BPMC"],"gpt_icon":0},{"id":"2455637143","title":"巴克莱银行将目标价从75美元上调至105美元适用于Blueprint Medicines Corporation。","url":"https://stock-news.laohu8.com/highlight/detail?id=2455637143","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455637143?lang=zh_cn&edition=full","pubTime":"2024-07-29 18:16","pubTimestamp":1722248168,"startTime":"0","endTime":"0","summary":null,"market":"uk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BPMC","BARC.UK","BK4139","LU0345777659.USD","BCS","BK4521","LU0047473722.SGD","LU0345777147.USD","BK4207","LU1078025761.USD","LU0047473722.EUR","BK4505","LU1791807156.HKD","LU0053671581.USD","LU0106831901.USD","LU0161305163.EUR","LU0964806797.USD","LU1668664300.SGD","LU0550127509.SGD","BK5152"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.blueprintmedicines.com","stockEarnings":[{"period":"1week","weight":-0.097},{"period":"1month","weight":0.0486},{"period":"3month","weight":-0.0324},{"period":"6month","weight":-0.122},{"period":"1year","weight":0.4166},{"period":"ytd","weight":-0.0223}],"compareEarnings":[{"period":"1week","weight":-0.0177},{"period":"1month","weight":0.0061},{"period":"3month","weight":0.0527},{"period":"6month","weight":0.1101},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.2374}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"蓝图医药公司于2008年10月14日在特拉华州成立，是一家生物制药公司，专注于改善患者的异常活化蛋白激酶基因组驱动的疾病定义的生命。该公司的做法是系统性和可重复鉴定激酶是基因组疾病定义驱动器和手艺的候选药物与治疗窗户，提供显著和持久的临床反应的患者。该公司正致力于几乎所有的努力研发，最初的市场开发，提高资本。该公司是受一些风险相似的其他早期阶段的公司，包括关键个人的依赖;需要开发商业上可行的药物;其他公司，其中有许多是更大和更好的资本竞争;并需要获得足够的额外资金，其药物的开发提供资金。如果公司无法筹集资金需要时或有吸引力的条件，这将被迫推迟，减少，消除或超出许可它的某些研究和开发项目或今后的商业化努力。","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":-0.056044},{"month":2,"riseRate":0.666667,"avgChangeRate":0.012381},{"month":3,"riseRate":0.777778,"avgChangeRate":0.045895},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.022821},{"month":5,"riseRate":0.7,"avgChangeRate":0.090385},{"month":6,"riseRate":0.6,"avgChangeRate":0.061595},{"month":7,"riseRate":0.7,"avgChangeRate":0.014145},{"month":8,"riseRate":0.7,"avgChangeRate":0.055409},{"month":9,"riseRate":0.6,"avgChangeRate":0.028138},{"month":10,"riseRate":0.4,"avgChangeRate":-0.027795},{"month":11,"riseRate":0.6,"avgChangeRate":0.044577},{"month":12,"riseRate":0.555556,"avgChangeRate":0.045056}],"exchange":"NASDAQ","name":"Blueprint Medicines Corporation","nameEN":"Blueprint Medicines"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Blueprint Medicines Corporation(BPMC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Blueprint Medicines Corporation(BPMC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Blueprint Medicines Corporation,BPMC,Blueprint Medicines Corporation股票,Blueprint Medicines Corporation股票老虎,Blueprint Medicines Corporation股票老虎国际,Blueprint Medicines Corporation行情,Blueprint Medicines Corporation股票行情,Blueprint Medicines Corporation股价,Blueprint Medicines Corporation股市,Blueprint Medicines Corporation股票价格,Blueprint Medicines Corporation股票交易,Blueprint Medicines Corporation股票购买,Blueprint Medicines Corporation股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Blueprint Medicines Corporation(BPMC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Blueprint Medicines Corporation(BPMC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}

公司概况